CRIS
Permanent URI for this communityhttps://investigadores.udd.cl/handle/123456789/1
Browse
39 results
Search Results
Now showing 1 - 10 of 39
- Some of the metrics are blocked by yourconsent settings
Item type:Publication, How I Do It: Evaluating Cardiac Implantable Devices and Noncardiac Mimics on Chest Radiographs(Radiological Society of North America (RSNA), 2025-05-01); Jared D. ChristensenThis article provides a comprehensive review of the radiographic appearances of cardiac implantable electronic devices, other cardiac support apparatuses, and similar-appearing noncardiac devices, emphasizing the importance of accurate identification and evaluation for potential complications.6 - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Scopus© Citations 7 2 - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Clinical Profile of Stroke Chameleons Receiving Intravenous Thrombolysis: Insights from a Single-Center Experience(S. Karger AG, 2024-11-13); ; ; ; Eloy Mansilla<jats:p>Introduction: In emergency rooms (ERs), 5% of patients experiencing an acute ischemic stroke (AIS) receive an alternative diagnosis; these cases are known as stroke chameleons (SC). The percentage of SC treated with intravenous thrombolysis (IVT) and the characteristics have not been well described. We aimed at investigating the variables associated with the probability receiving IVT. Methods: In this prospective study, we included consecutive patients with SC admitted at the ER of Clínica Alemana between September 2014 and October 2023. Results: Among 1,193 stroke patients; sixty-three (5.2%) corresponded to SC. Ten of these cases (15.8%, 95% CI: 8.8–26.8) were treated with IVT, mean door-to-needle (DTN) time of 85.7 (SD 35) min, median of 73.5 (IQR 62–113) min. SCs who underwent IVT were younger (p = 0.01), with higher NIHSS (p = 0.05). They presented more frequently with altered level of consciousness in the NIHSS (p = 0.01), language abnormities (p = 0.001), and dysarthria (p = 0.01). In multivariate analysis, none of the variables were significantly associated with IVT. A secondary analysis showed that only time to brain imaging was significantly associated with IVT (OR: 0.99; 95% CI: 0.98–0.99; p = 0.01). Conclusions: Almost 1 out of every 7 SC could be treated with IVT but with a prolonged DTN time; the chance of being treated is associated with time to brain imaging. <p>Introduction: In emergency rooms (ERs), 5% of patients experiencing an acute ischemic stroke (AIS) receive an alternative diagnosis; these cases are known as stroke chameleons (SC). The percentage of SC treated with intravenous thrombolysis (IVT) and the characteristics have not been well described. We aimed at investigating the variables associated with the probability receiving IVT. Methods: In this prospective study, we included consecutive patients with SC admitted at the ER of Clínica Alemana between September 2014 and October 2023. Results: Among 1,193 stroke patients; sixty-three (5.2%) corresponded to SC. Ten of these cases (15.8%, 95% CI: 8.8–26.8) were treated with IVT, mean door-to-needle (DTN) time of 85.7 (SD 35) min, median of 73.5 (IQR 62–113) min. SCs who underwent IVT were younger (p = 0.01), with higher NIHSS (p = 0.05). They presented more frequently with altered level of consciousness in the NIHSS (p = 0.01), language abnormities (p = 0.001), and dysarthria (p = 0.01). In multivariate analysis, none of the variables were significantly associated with IVT. A secondary analysis showed that only time to brain imaging was significantly associated with IVT (OR: 0.99; 95% CI: 0.98–0.99; p = 0.01). Conclusions: Almost 1 out of every 7 SC could be treated with IVT but with a prolonged DTN time; the chance of being treated is associated with time to brain imaging. </p></jats:p>1 - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Early prediction of functional mobility severity after stroke: two key milestones(2024) ;Patricia Vargas ;Marcos Maldonado-DiazTania Gutiérrez-PanchanaScopus© Citations 2 - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Excess burden of antibiotic-resistant bloodstream infections: evidence from a multicentre retrospective cohort study in Chile, 2018–2022(2024) ;Kasim Allel ;Anne Peters ;Hassan Haghparast-Bidgoli ;Maria Spencer-SandinoJose ConejerosScopus© Citations 2 4 - Some of the metrics are blocked by yourconsent settings
Item type:Publication, ¿Ha disminuido la colectomía por crisis de colitis ulcerosa?(2023) ;Nicolás Besser ;Erika Chacón ;Andrés Iglesias ;Manuel Álvarez-LobosCarolina Pavez1 - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Effectiveness of the second COVID-19 booster against Omicron: a large-scale cohort study in Chile(2023) ;Alejandro Jara ;Cristobal Cuadrado ;Eduardo A. Undurraga ;Christian GarcíaManuel Nájera<jats:title>Abstract</jats:title><jats:p>In light of the ongoing COVID-19 pandemic and the emergence of new SARS-CoV-2 variants, understanding the effectiveness of various booster vaccination regimens is pivotal. In Chile, using a prospective national cohort of 3.75 million individuals aged 20 or older, we evaluate the effectiveness against COVID-19-related intensive care unit (ICU) admissions and death of mRNA-based second vaccine boosters for four different three-dose background regimes: BNT162b2 primary series followed by a homologous booster, and CoronaVac primary series followed by an mRNA booster, a homologous booster, and a ChAdOx-1 booster. We estimate the vaccine effectiveness weekly from February 14 to August 15, 2022, by determining hazard ratios of immunization over non-vaccination, accounting for relevant confounders. The overall adjusted effectiveness of a second mRNA booster shot is 88.2% (95%CI, 86.2–89.9) against ICU admissions and 90.5% (95%CI 89.4–91.4) against death. Vaccine effectiveness shows a mild decrease for all regimens and outcomes, probably linked to the introduction of BA.4 and BA.5 Omicron sub-lineages and the waning of immunity. Based on our findings, individuals might not need additional boosters for at least 6 months after receiving a second mRNA booster shot in this setting.</jats:p>Scopus© Citations 11 2 - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Variability in care for children with severe acute asthma in Latin America(2020) ;Nicolas Monteverde‐Fernandez ;Franco Diaz‐Rubio ;Pablo Vásquez‐Hoyos ;Alexandre T. RottaSebastián González‐Dambrauskas12Scopus© Citations 5 - Some of the metrics are blocked by yourconsent settings
Item type:Publication, COVID-19 Lockdown Effects on Acute Stroke Care in Latin America(2021) ;Virginia A. Pujol-Lereis ;Alan Flores ;Miguel A. Barboza ;Carlos Abanto-ArgomedoPablo AmayaScopus© Citations 12 4 - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Proteinuria in Hantavirus Cardiopulmonary Syndrome: A Frequent Finding Linked To Mortality(2021); ;Gregory Mertz; ;Mauricio EspinozaMarcela Ferrés27Scopus© Citations 4